N/A N=12 Carbohydrate Availability and microRNA Expression
Glycogen Depletion
Primary: Fold Change in microRNA Expression From Baseline — 0.73; 1.36 fold change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=29 Effect of High Carbohydrate vs. Low Carbohydrate Diet in Type 2 Diabetes
Diabetes Mellitus · Diabetes Mellitus, Type 2
Primary: Hepatic Glycogen Content and Rates of Gluconeogenesis in Subjects With Type 2 Diabetes — 8.2; 9.4; 17.4; 15.6 umol/kgFFM/min
N/A N=10 High Altitude and Exogenous Carbohydrate Oxidation
Glucose Metabolism · High Altitude
Primary: Rate of Exogenous Carbohydrate Oxidation — 0.44; 0.35 g/min
N/A N=33 Training Effects on Skeletal Muscle Fatty Acid Metabolism
Healthy Volunteers
Primary: Insulin Sensitivity as Measured by Hyperinsulinemic Euglycemic Clamp at a Single Time Point (6 Hrs) After Intralipid or Glycerol Infusion — 8; 12; 6; 11 M value — p=<0.05
N/A N=16 The Effect of Hydration Status on Glycemic Control and Appetite Regulation
Healthy
Primary: Glycemic Response — 303; 306 mmol*120 min*l-1 — p=0.886
N/A N=20 Essential Amino Acids and Protein Kinetics During Caloric Deprivation
Muscle Protein Synthesis · Whole-body Protein Balance
Primary: Postprandial, Resting Muscle Protein Synthesis Rates — 0.055; 0.061 percent per hour
Phase 2 N=10 Measurement of Glucose/Glycogen Metabolism in Humans Using Magnetic Resonance at 4 or 7 Tesla
Type 1 Diabetes
Primary: Brain Glycogen Turnover Rate — 0.31; 0.28 mg/kg/min
Phase 3 N=30 SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2
Type II Diabetes Mellitus
Primary: Change in Plasma Glucose Concentration — -29.7; -17.2; 3.1; 0.9 mg/dl
Phase 4 N=8 Effects of Pioglitazone on Exogenous Carbohydrate Oxidation During Steady-State Exercise at High Altitude
High Altitude
Primary: Rate of Exogenous Glucose Oxidation — 0.31; 0.32 g/min
N/A N=12 Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver
Type 1 Diabetes Mellitus
Primary: Assess Difference in Hepatic Glycogen Measured in the Fasting State Before vs. After Repeated Glucagon Administration — 6.5 g/L
N/A N=37 Forearm Immobilization, Metabolic Health, and Muscle Loss
Healthy
Primary: Percent Change in Forearm Glucose Uptake — -73; 127; -95 Percent change in clamp FGU with immob
N/A N=21 Physical Training and the Incretin Effect
Healthy
Primary: Incretin Effect (the % of Insulin Secreted Due to the Release of the Intestinal Hormones Glucagon Like Peptide-1 (GLP-1 and Glucose-dependent Insulinotropic Peptide…
N/A N=60 Dietary Carbohydrate Manipulation and Energy Balance: RCT
Physical Activity · Diet Modification
Primary: Physical Activity Energy Expenditure (kJ/Day or kcal/Day) — 1229; 1096; 1275; 1142 kcal/d
N/A N=37 A Pilot Study: Snacking, Willpower and Glucose Availability
Willpower
Primary: Responses to the Control of Eating Questionnaire — 4.5; 5.2; 5.1; 5.2 units on a scale
Phase 1 N=14 Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)
Glucose Transporter Type 1 Deficiency Syndrome · GLUT1 Deficiency Syndrome
Primary: Number of Participants With Reduction in Spike-wave Fraction of the EEG Recording Time — 13 Participants
Phase 2 N=83 IV Glucose for Dehydration Treatment
Dehydration
Primary: Measurement of Serum Ketones Before and After Administration of Intravenous Fluids for Acute Gastroenteritis — 1.10; 2.39 mmol/L — p=0.0003
N/A N=14 Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes
Diabetes Mellitus, Type 1 · Autoimmune Diseases · Diabetes Mellitus
Primary: HbA1c, Glycated Hemoglobin — 7.9; 8.3; 8.0; 8.4 percentage of total hemoglobin
N/A N=27 Erythrocyte and Adipocyte G6PD Activity Levels in Obesity
Diabetes · Obesity
Primary: Measure Erythrocyte G6PD Levels in Diabetic vs. Non-diabetic Morbidly Obese Patients Undergoing Laparoscopic Gastric Bypass. — 3.12; 0.67; 22; 13 nM/min/mg — p=<0.05
Phase 4 N=50 Physiological and Psychological Effects of Testosterone During Severe Energy Deficit and Recovery
Caloric Restriction · Exercise
Primary: Body Composition at the End of Each Study Phase — 78.3; 78.0; 73.3; 75.8 kilograms
N/A N=10 Glucagon and Advanced HCL System to Prevent Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
Type 1 Diabetes · Hypoglycemia
Primary: Difference in Percentage of Time in Target Glucose Range (PG: 3.9 - 10.0 mmol/l) During and for 1-hour After Dynamic Physical Exercise Between Visit B and C — 100; 100…
Phase 2 N=20 Acute Effects of Exogenous Ketone Ester Administration in Heart Failure
Heart Failure With Preserved Ejection Fraction
Primary: Maximal Exercise Capacity (Peak VO2) Assessed by Cardiopulmonary Exercise Testing — 1.0; 1.0 L/min
N/A N=12 Nighttime Feeding and Morning Endurance Performance
Poor Performance Status
Primary: Running Performance — 52.8; 52.8 minutes
N/A N=45 Carnosine Loading and Periodized Training in MS and HC
Multiple Sclerosis · Exercise Therapy · Dietary Supplement
Primary: VO2max — 40.4; 41.2; 44; 43.4 ml/kg/min
Phase 1 N=10 The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA
Healthy Participants
Primary: Rates of Hepatic Mitochondrial Oxidation — 262; 149 micromol/min
N/A N=34 Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients
Parkinson's Disease · Multiple Sclerosis
Primary: Blood Lactate Response — 1.7; 1.6; 1.2; 2.3 mmol/L
N/A N=90 Exercise Training and Glucose Metabolism in Aging
Type 2 Diabetes Mellitus · Impaired Glucose Tolerance (Prediabetes)
Primary: Baseline Glucose Utilization — 0.0062; 0.0035 µmol/kgFFM/pmol insulin/min
Phase 2 N=16 The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Glycemic Response During Exercise and Early Recovery — 86; 85; 174; 161 mg/dL — p=<0.001
Phase 3 N=30 Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin
Type II; Diabetes
Primary: Measurement of the Change in Plasma Glucose (mg/dL): Study 1 — -29; -17 mg/dl
Phase 2 N=51 Peanuts and Glycemic Control
Type2 Diabetes · Cardiovascular Diseases
Primary: Fasting Plasma Glucose — -0.9; -0.4 mg/dL
N/A N=56 Effect of Dietary Glycemic Index on Beta-cell Function
Impaired Glucose Tolerance · Oxidative Stress · Prediabetes
Primary: Disposition Index — 708; 793; 791 unitless